抗逆轉錄病毒藥物市場 - 副產品（蛋白酶抑制劑、整合酶抑制劑、多類組合產品、NRTI、NNRTI）、類型（品牌、學名藥）、年齡層、配銷通路- 全球預測，2024 年 - 2032 年

Anti-retroviral Drugs Market - By Product (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, NRTIs, NNRTIs), Type (Branded, Generic), Age Group, Distribution Channel - Global Forecast, 2024 - 2032

出版日期: 2024年02月27日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於針對這些藥物的研究激增，2024 年至 2032 年間，全球抗愛滋病毒藥物市場規模的CAGR將超過 4.2%。隨著愛滋病毒/愛滋病治療方法的不斷探索和新病毒株的出現，製藥公司正在大力投資研發，以增強現有藥物並發現新的治療選擇。

例如，2023 年12 月，根據《神經病學年鑑》上發表的一項研究，過去十年的大量病例報告表明了一種相關性：患有多發性硬化症(MS) 的個體開始針對HIV 進行抗逆轉錄病毒治療，主要是為了控制病毒，觀察到 MS 症狀完全消失或疾病進展明顯減慢。該研究表明，抗逆轉錄病毒藥物可能會影響多發性硬化症的可能性，從而揭示了愛滋病毒治療和多發性硬化症管理之間可能的關係。

這些努力導致發現了更有效的藥物配方、改進的給藥方法並減少了副作用，從而推動了對抗逆轉錄病毒藥物的需求。此外，對病毒抗藥性機制和個人化醫療方法的不斷了解進一步推動了市場的成長。隨著研究不斷發現新的見解，對抗逆轉錄病毒藥物的需求預計將持續存在，這為愛滋病毒/愛滋病及相關疾病的管理帶來更好的結果。

整個抗逆轉錄病毒藥物產業根據產品、類型、年齡層、配銷通路和地區進行分類。

到 2032 年，核苷逆轉錄酶抑制劑 (NRTI) 領域將出現顯著成長。因此，NRTI 在控制愛滋病毒/愛滋病、推動市場需求方面發揮著至關重要的作用。隨著 NRTI 配方和組合的不斷進步，與其經過驗證的功效和安全性相一致，抗逆轉錄病毒藥物市場的需求持續成長，確保了這一重要醫學領域的持續研究和開發。

從 2023 年到 2032 年，學名藥領域的抗逆轉錄病毒藥物市場佔有率將保持主導地位。學名藥抗逆轉錄病毒藥物為品牌藥物提供了具有成本效益的替代品，使愛滋病毒治療在全球範圍內更容易獲得。它們的負擔能力有利於廣泛分配，特別是在獲得醫療資源有限的低收入和中等收入國家。此外，學名藥抗逆轉錄病毒藥物經過嚴格的監管審查，以確保品質和功效，增強醫療保健提供者和患者的信心。由於對負擔得起的愛滋病毒治療的需求持續存在，對學名藥抗逆轉錄病毒藥物的需求仍然強勁，推動了市場成長並改善了全世界獲得救命藥物的機會。

2024年至2032年，歐洲抗愛滋病毒藥物市場將呈現出值得稱讚的複合CAGR。進行有效的疾病管理。此外，嚴格的法規確保了抗愛滋病毒藥物的品質和安全，增強了消費者的信任。由於歐洲國家優先考慮愛滋病毒預防和治療等公共衛生舉措，對這些藥物的需求保持穩定。此外，持續的研發工作推動創新，進一步刺激整個歐洲對先進抗病毒療法的需求。

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson and Johnson
Merck & Co, Inc.
Pfizer Inc.
Viatris Inc.

簡介目錄

Product Code: 8298

Global Anti-retroviral Drugs Market size will witness over 4.2% CAGR between 2024 and 2032 due to the surge in research and studies dedicated to these medications. With the ongoing exploration of HIV/AIDS treatments and the emergence of new strains, pharmaceutical companies are investing heavily in research and development to enhance existing drugs and discover novel therapeutic options.

For instance, in December 2023, as per a study published in the Annals of Neurology, numerous case reports over the past decade indicated a correlation: individuals with multiple sclerosis (MS) who initiated anti-retroviral therapy for HIV, primarily to manage the virus, observed either complete disappearance of MS symptoms or a marked deceleration in disease progression. The research suggested that anti-retrovirals may potentially impact the likelihood of developing MS, shedding light on a possible relationship between HIV treatment and MS management.

These efforts have led to the identification of more effective drug formulations, improved delivery methods, and reduced side effects, thereby driving demand for anti-retroviral drugs. Moreover, the expanding understanding of viral resistance mechanisms and personalized medicine approaches further fuels market growth. As research continues to uncover new insights, the demand for anti-retroviral drugs is expected to persist, offering hope for better outcomes in the management of HIV/AIDS and related conditions.

The overall anti-retroviral drugs Industry is classified based on the product, type, age group, distribution channel, and region.

The nucleoside reverse transcriptase inhibitors (NRTIs) segment will register significant growth by 2032. These drugs, a cornerstone of HIV treatment, inhibit the virus's ability to replicate by targeting its reverse transcriptase enzyme. As a result, NRTIs play a crucial role in managing HIV/AIDS, driving demand within the market. With ongoing advancements in NRTI formulations and combinations, in line with their proven efficacy and safety profiles, the demand for the Anti-retroviral Drugs Market continues to rise, ensuring continued research and development in this vital area of medicine.

Anti-retroviral drugs market share from the generic segment will withhold a dominant share from 2023-2032. Generic anti-retroviral drugs offer cost-effective alternatives to branded medications, making HIV treatment more accessible globally. Their affordability facilitates widespread distribution, particularly in low- and middle-income countries where access to healthcare resources is limited. Moreover, generic anti-retrovirals undergo rigorous regulatory scrutiny to ensure quality and efficacy, bolstering confidence among healthcare providers and patients. As the need for affordable HIV treatment persists, the demand for generic anti-retroviral drugs remains strong, driving market growth and improving access to life-saving medications worldwide.

Europe anti-retroviral drugs market will showcase a commendable CAGR from 2024 to 2032. With a strong healthcare infrastructure and a high prevalence of HIV/AIDS in certain regions, the continent relies on these medications for effective disease management. Additionally, stringent regulations ensure the quality and safety of anti-retroviral drugs, bolstering consumer trust. As European countries prioritize public health initiatives, including HIV prevention and treatment, the demand for these drugs remains steady. Moreover, ongoing research and development efforts drive innovation, further fueling the demand for advanced anti-retroviral therapies across Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing investment in research and development
  - 3.2.1.2 Growing burden of HIV
  - 3.2.1.3 Increase in availability of novel drugs for treatment of HIV
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with the drugs
  - 3.2.2.2 High cost of the treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Protease inhibitors
5.3 Integrase inhibitors
5.4 Multi-class combination products
5.5 Nucleoside reverse transcriptase inhibitors (NRTIs)
5.6 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Branded
6.3 Generic

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Adult
7.3 Pediatric
7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa